UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000034954 |
|---|---|
| Receipt number | R000039856 |
| Scientific Title | Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets -Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS)- |
| Date of disclosure of the study information | 2018/11/30 |
| Last modified on | 2021/04/22 10:40:16 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets
-Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS)-
Acronym
Phase 1/2a Study of Ropinirole Hydrochloride Extended-Release Tablets in Patients with Amyotrophic Lateral Sclerosis (ALS)
Scientific Title
Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets
-Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS)-
Scientific Title:Acronym
Phase 1/2a Study of Ropinirole Hydrochloride Extended-Release Tablets in Patients with Amyotrophic Lateral Sclerosis (ALS)
Region
| Japan |
Condition
Condition
amyotrophic lateral sclerosis (ALS)
Classification by specialty
| Neurology |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
To exploratively assess the safety and tolerability of ropinirole hydrochloride, in terms of delay in the progression of ALS, after oral treatment in ALS patients.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The kind, frequency, severity and extent of adverse events, transition of laboratory values and the percentage of discontinued cases during double blined 24 weeks.
Key secondary outcomes
After double blined 24 weeks,
1) Ratio of change in ALSFRS-R score per 4 weeks before and after treatment start
2) Change in ALSFRS-R score at 24 weeks in double-blind phase (double-blind day 1 to 24)
3) Change in ALSFRS-R score of the continuation period (final evaluation from first evaluation in continuation phase) and the whole administration period (day 1 in double-blind phase to final evaluation in continuation phase)
4) Completed Assessment of Function and Survival (CAFS) score at double-blind phase 24 weeks (day 1 to 24 weeks in double-blinded phase), continuation period (first evaluation to final evaluation in continuation phase) and whole administration period (day 1 in double-blind phase to final evaluation in continuation phase)
5) Combined evaluation by converting the following items into Z scores and adding them together
･Subscore for each ALSFRS-R domain (bulbar function, limb function, breathing function)
･ALS severity score
･Simple respiratory function test (FEV 1, FEV 6)
･Precise respiratory function test (VC, %FVC, FEV1%)
･Manual Muscle Test (MMT) score (limbs, trunk) and quantitative muscular strength
･Grip strength, pinch strength
･Modified Norris Scale (Bulbar Symptom Score)
･Tongue pressure
･Weight
･Physical activities, number of steps
･Objective muscle mass by skeletal muscle CT
･ALSAQ-40 score
6) Period until death or certain disease progression (death, inability to walk independently, abolition of one side upper limb function, tracheostomy, wearing of artificial respiratory equipment, intubation of nutrition, loss of practical conversation)
7) Period up to %FVC < 50%
8) Period until ALSFRS-R score decreased by 6 or more
9) Percentage of discontinued cases from day 1 in double-blind phase to final evaluation in continuation phase
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Once daily ropinirole hydrochloride extended-release tablet with dose-escalation tolerable from 2mg to 16mg for double blinded 24 weeks
Interventions/Control_2
Once daily placebo tablet with dose-escalation tolerable from 2mg to 16mg for 24 weeks (Interventions)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
(At provisional registration)
(1) Patients falling under probable laboratory-supported ALS, Clinically probable ALS or Clinically definite ALS in ALS diagnostic criteria (revised El Escorial criteria by the World Federation of Neurology), and within 60 months after onset
(2) Patients with severity classification of ALS (Ministry of Health, Labor and Welfare Specific Disease Research 2007.1.1) of 1 or 2
(3) Japanese patients who aged 20 to 80 years old
(4) Patients with the all items in ALSFRS-R (patients with the item in writing and feeding behavior (1) on one or both sides of 2 or more points) of 2 or more points
(5) Patients with percent FVC more than 70
(6) Patients who can submit written informed consent. If patients are duly capable of study consent but are unable to sign by themselves due to aggravation of disease condition, written informed consent can be obtained from a legally authorized representative who can sign on behalf of the patients after confirming the patients' agreement to study participation.
(7) Patients eligible for outpatient visit (and hospitalization) during trial period
(At definitive registration)
(8) Patients whose change in ALSFRS-R score is between -2 to -5 during 12 weeks of observation phase
(9) Patients who have not newly introduced riluzole since the start of observation phase, and who have not changed or discontinued the dose of riluzole
(10) Patients who did not administered edaravone and high-dose mecobalamin (25 mg or 50 mg) since the start of observation phase
(11) Patients eligible for outpatient visit (and hospitalization) during trial period
Key exclusion criteria
(1) Patients with severe diseases such as hepatic disorder, kidney disorder, heart disease, lung disease, blood disorder, metabolic disorder and whom investigators judged inappropriate for trial
(2) Patients who participated in other clinical trials within 30 days prior to provisional registration
(3) Patients with cancer complicated, or not more than 5 years after cure
(4) Patients who have used ropinirole hydrochloride
(5) Patients with family history of ALS with SOD-1 mutation or who have previously been diagnosed with ALS with SOD-1 mutations
(6) Pregnant women or women who may be pregnant, lactating women
(7) Patients with orthostatic hypotension with subjective symptoms (dizziness, syncope etc.)
(8) Patients who have psychiatric disorders or psychiatric symptoms and are considered difficult to participate in this trial
(9) Patients whom investigators judged as inappropriate for trial
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | Jin |
| Middle name | |
| Last name | Nakahara |
Organization
Keio University Hospital
Division name
Department of Neurology
Zip code
160-0016
Address
35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
TEL
03-3353-1211
nakahara@a6.keio.jp
Public contact
Name of contact person
| 1st name | Shinichi |
| Middle name | |
| Last name | Takahashi |
Organization
Keio University Hospital
Division name
Department of Neurology
Zip code
160-0016
Address
35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
TEL
03-3353-1211
Homepage URL
https://www.neurology.med.keio.ac.jp
takashin@tka.att.ne.jp
Sponsor or person
Institute
Keio University Hospital
Institute
Department
Personal name
Funding Source
Organization
Japan Agency of Medical Research and Development (AMED)
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
K Pharma, Inc
IRB Contact (For public release)
Organization
Keio University Hospital Institutional Review Board
Address
35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan
Tel
03-3353-1211
keio-chiken@adst.keio.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 11 | Month | 30 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
21
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2018 | Year | 10 | Month | 04 | Day |
Date of IRB
| 2018 | Year | 11 | Month | 01 | Day |
Anticipated trial start date
| 2018 | Year | 12 | Month | 05 | Day |
Last follow-up date
| 2020 | Year | 11 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
| 2021 | Year | 01 | Month | 08 | Day |
Date analysis concluded
| 2021 | Year | 03 | Month | 08 | Day |
Other
Other related information
Management information
Registered date
| 2018 | Year | 11 | Month | 20 | Day |
Last modified on
| 2021 | Year | 04 | Month | 22 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039856
